Contact us for free information or to start a free case review.
Crestor, a cholesterol lowering drug, was approved for the U.S. one year ago, quickly generating sales of $465 million through the end of the second quarter. AstraZeneca''s nearly $4 billion in annual sales of the drug has been the target of some controversy. Public Citizen consumer group demanded Crestor be withdrawn in March and asked the FDA to start a criminal investigation of AstraZeneca in August, saying the company violated regulations requiring companies to report within 15 days cases of serious complications in people taking their medications.
The consumer group has said there were 23 cases involving Crestor patients that went unreported for as long as 97 days. All statin drugs like Crestor have been linked to rhabdomyolysis, a rare and sometimes fatal condition causing severe muscle weakness. Now, AstraZeneca is trying to keep sales up and has started to alter its marketing for Crestor. In July, the company introduced a Website addressing the Crestor safety concerns, as well as providing a telephone number so patients can directly call the company.
Copyright © 2001 - 2012 Online Lawyer Source
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.